QPS, a global contract research organization (CRO), has expanded and upgraded its high-resolution mass spectrometers (HRMS), with the addition of three new TripleTOF HRMS systems for GLP quantitation, two in the Newark, DE facility and one in the Suzhou, China lab.

As part of this expansion, QPS has hired Larry Mallis, Ph.D., Director of Bioanalysis, to lead the newly merged biotherapeutics and biomarkers Liquid Chromatography–Mass Spectrometry (LC-MS) quantitation team in Delaware.

The QPS facility in Newark, DE, now has four high-resolution mass spectrometers: two 6600+, one 6600, and one 5600, all of which are being used for Good Laboratory Practice (GLP) quantitation and metabolite identification.

“QPS has been closely watching the trends in the market and we are committed to responding to the needs of our clients by dedicating four of the five TripleTOF® Ultra-Performance Liquid Chromatography–High-Resolution Mass Spectrometry (UPLC-HRMS) systems to quantitation of oligonucleotides and intact proteins,” said John Kolman, VP, Global Head of Translational Medicine, QPS LLC.

Larry Mallis, Ph.D., began his career in the pharmaceutical industry (BMS, Wyeth, and Merck), before moving into the CRO industry, most recently as Director of Bioanalytical Operations at Lovelace Biomedical Research Institute. This new group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of rare diseases. This group has expertise in the quantitation of oligonucleotides, peptides, intact proteins, and highly hydrophilic low-molecular-weight metabolite biomarkers by UPLC-HRMS, or by immunoaffinity UPLC-MS/MS (tandem mass spectrometry), or by hybridization-LC-fluorescence.